Bismuth Subcitrate Potassium, Metronidazole And Tetracycline Hydrochloride Capsule
NDC Package 49884-151-54
Package Information
Bismuth Subcitrate Potassium, Metronidazole And Tetracycline Hydrochloride capsules is bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules in combination with omeprazole are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. This formulation utilizes a capsule delivery system. Marketed by Par Health Usa, Llc, this product is identified by NDC 49884-151 and is authorized under FDA application ANDA205770.
Identification & Billing
- RxCUI: 1294619 - bismuth subcitrate 140 MG / metroNIDAZOLE 125 MG / tetracycline HCl 125 MG Oral Capsule
- RxCUI: 1294619 - bismuth subcitrate 140 MG / metronidazole 125 MG / tetracycline hydrochloride 125 MG Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 49884 - Par Health Usa, Llc
- 49884-151 - Bismuth Subcitrate Potassium, Metronidazole And Tetracycline Hydrochloride
- 49884-151-54 - 120 CAPSULE in 1 CARTON
- 49884-151 - Bismuth Subcitrate Potassium, Metronidazole And Tetracycline Hydrochloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 49884-151-54 identifies a specific commercial package of 120 capsule in 1 carton of Bismuth Subcitrate Potassium, Metronidazole And Tetracycline Hydrochloride, a human prescription drug labeled by Par Health Usa, Llc. This capsule is formulated for oral use and contains bismuth subcitrate potassium; metronidazole; tetracycline hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Par Health Usa, Llc on March 07, 2023. The current certification is valid through December 31, 2027.
How is this Par Health Usa, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 49884015154. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 120 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.